Item 8.01. Other Events.
On December 15, 2020, ARCA biopharma, Inc., or the Company, announced that the
first patients have been enrolled in ASPENCOVID19, the Phase 2b clinical trial
evaluating rNAPc2 (AB201) as a potential treatment for patients hospitalized
with COVID-19. The first patient was enrolled at the University of Colorado
Hospital on December 10, 2020, with a total of 5 patients randomized to date.
The Company currently anticipates topline trial data from this Phase 2b clinical
trial in the second quarter of 2021. The press release related to these items is
filed as Exhibit 99.1 hereto, the contents of which are incorporated herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press Release titled "ARCA biopharma Announces First
Patients Enrolled in ASPENCOVID19 Phase 2b Clinical Trial
Evaluating rNAPc2 (AB201) as a Potential Treatment for
COVID-19" dated December 15, 2020 .
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses